Diseases / Venous Thromboembolism
Venous Thromboembolism
DiseaseVenous thromboembolism encompasses deep vein thrombosis and pulmonary embolism, caused by abnormal clot formation in venous circulation. It is a major source of preventable morbidity and mortality.
- Trials
- 686
- Recruiting
- 85
- Completed
- 403
- With results
- 119
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | — | — | — | 5 | 1 | — | — | 1 | 9 |
| Phase 1 | 3 | — | — | — | 13 | 2 | — | — | — | 18 |
| Phase 1/2 | — | — | — | — | 3 | — | — | — | — | 3 |
| Phase 2 | 4 | — | 1 | — | 43 | 12 | 3 | — | 2 | 65 |
| Phase 2/3 | 2 | 1 | — | — | 7 | 1 | — | — | 3 | 14 |
| Phase 3 | 16 | 5 | — | — | 73 | 15 | 2 | — | 7 | 118 |
| Phase 4 | 11 | 2 | 1 | — | 35 | 9 | 3 | — | 6 | 67 |
| Not applicable | 18 | 9 | 2 | 3 | 52 | 6 | 3 | 2 | 13 | 108 |
| Unknown | 29 | 6 | 1 | 8 | 172 | 13 | 7 | — | 48 | 284 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Venous Thromboembolism | 9 | 18 | 3 | 65 | 14 | 118 | 67 | 108 | 284 | 686 |
| Venous Thrombosis | 5 | 6 | 1 | 18 | 4 | 38 | 18 | 32 | 71 | 193 |
| Pulmonary Embolism | 7 | 6 | 2 | 8 | 3 | 32 | 16 | 32 | 73 | 179 |
| Thrombosis | 2 | — | — | 4 | 3 | 12 | 8 | 5 | 23 | 57 |
| Neoplasms | 1 | 1 | — | 6 | — | 13 | 3 | 4 | 27 | 55 |
| Thromboembolism | 1 | 2 | — | 5 | — | 11 | 2 | 1 | 21 | 43 |
| Atrial Fibrillation | — | — | — | 4 | — | 2 | 4 | 6 | 19 | 35 |
| Hemorrhage | — | — | — | 3 | 1 | 9 | 4 | 2 | 10 | 29 |
| Cardiovascular Diseases | — | 1 | — | — | — | 1 | 2 | 2 | 15 | 21 |
| Embolism and Thrombosis | — | 2 | — | 2 | — | 2 | 1 | — | 6 | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Bayer | 35 | 10 |
| 2 | Ottawa Hospital Research Institute | 21 | 6 |
| 3 | University Hospital, Brest | 19 | 7 |
| 4 | Boehringer Ingelheim | 16 | 4 |
| 5 | McMaster University | 14 | 5 |
| 6 | Brigham and Women's Hospital | 13 | 0 |
| 7 | Sanofi | 13 | 9 |
| 8 | University of Utah | 11 | 0 |
| 9 | Bristol-Myers Squibb | 10 | 0 |
| 10 | Daiichi Sankyo | 9 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Enoxaparin | 87 |
| 2 | Rivaroxaban | 87 |
| 3 | apixaban | 58 |
| 4 | Warfarin | 30 |
| 5 | Dalteparin | 29 |
| 6 | Heparin, Low-Molecular-Weight | 29 |
| 7 | Aspirin | 28 |
| 8 | Dabigatran | 25 |
| 9 | edoxaban | 20 |
| 10 | Fondaparinux | 18 |
Evidence
- Results reported
- 29.5%119 of 403 completed
- Published
- 17.9%72 of 403 completed
- Primary endpoint met
- 48.9%45 of 92 analyses
- Median months to report
- 13
Documents disclosed
Trial profile
- Median enrollment
- 354
- Median duration
- 30months
- Countries
- 80
- Study sites
- 6653
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 30
- Phase 1
- 28
- Phase 1/2
- 102
- Phase 2
- 160
- Phase 2/3
- 145
- Phase 3
- 480
- Phase 4
- 128
- Not applicable
- 239
- Unknown
- 600
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 55 |
| 2 | Ottawa | Canada | 53 |
| 3 | Hamilton | Canada | 47 |
| 4 | Brest | France | 43 |
| 5 | Boston | United States | 42 |
| 6 | Montreal | Canada | 37 |
| 7 | Moscow | Russia | 37 |
| 8 | Vienna | Austria | 33 |
| 9 | Barcelona | Spain | 32 |
| 10 | Beijing | China | 32 |
Terminations
- Terminated
- 59
- Withdrawn
- 18
- Suspended
- 2
- Stopped for recruitment
- 3.2%22 of 686 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06189313 Suspended | Suspended | Enrollment in the study administratively paused pending modifications to the study device design | 2029-02-02 |
| NCT06129760 Suspended | Suspended | PI decision | 2027-12-31 |
| NCT05171075 Terminated | Terminated | Sponsor Decision | 2026-04-10 |
| NCT05171049 Terminated | Terminated | Sponsor decision | 2026-02-04 |
| NCT05104229 Withdrawn | Withdrawn | Limited Resources | 2026-01-01 |
| NCT06257290 Terminated | Terminated | Challenges in inclusion | 2025-10-10 |
| NCT05966740 Terminated | Terminated | 2025-04-28 | |
| NCT05033314 Terminated | Terminated | Study terminated due to slow recruitment. | 2024-10-01 |
| NCT05536791 Withdrawn | Withdrawn | No patients were screened in the study. | 2024-10-01 |
| NCT05887518 Withdrawn | Withdrawn | The study was canceled because the cost of the tests requested by the Turkish Medicines and Medical Devices Agency exceeded the project budget | 2024-10-01 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Venous Thromboembolism trials on ClinicalTrials.gov →